Engineered immune cells take on childhood arthritis and Lupus-Like diseases
NCT ID NCT07184450
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 35 times
Summary
This early-stage trial is testing a new type of CAR-T cell therapy in 11 children with severe, treatment-resistant rheumatic diseases like juvenile dermatomyositis and arthritis. The therapy uses the child's own immune cells, modified to target two proteins (BCMA and CD70) on faulty immune cells. The main goal is to check safety, but researchers will also look for signs of improvement in disease activity over six months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS (SSC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BCMA/CD70-targeted CAR-T cells
What this could lead to
If successful, this could offer a new treatment option for children with severe, hard-to-treat rheumatic diseases that haven't responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 11 participants, so results may not apply broadly. CAR-T therapy can cause serious side effects like cytokine release syndrome.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.